SouthState Corp’s Atea Pharmaceuticals AVIR Stock Holding History

SouthState Corp’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-565	Closed	-$1.7K	–	600
2023 Q3	$1.7K	Hold	565	–	–	﹤0.01%	574
2023 Q2	$2.11K	Hold	565	–	–	﹤0.01%	545
2023 Q1	$1.89K	Hold	565	–	–	﹤0.01%	602
2022 Q4	$2.72K	Buy	+565	New	+$2.86K	﹤0.01%	646
2022 Q3	–	Sell	-565	Closed	-$4K	–	681
2022 Q2	$4K	Hold	565	–	–	﹤0.01%	650
2022 Q1	$4K	Hold	565	–	–	﹤0.01%	651
2021 Q4	$5K	Sell	565 -1,435	-72%	-$22.4K	﹤0.01%	626
2021 Q3	$70K	Buy	+2,000	New	+$55.5K	0.01%	325

Other funds holding AVIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SouthState Corp's AVIR Position: Q4 2023 in Review

SouthState Corp sold out of Atea Pharmaceuticals (AVIR) in Q4 2023, closing a stake of 565 shares — an estimated $1.7K sold.

SouthState Corp first reported a position in AVIR in Q3 2021 and held it in 8 quarters. The position peaked at $70K in Q3 2021. 108 funds tracked by Wall St. Rank hold AVIR as of Q4 2023.

SouthState Corp reported no remaining Atea Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
SouthState Corp sold 565 Atea Pharmaceuticals shares in Q4 2023, an estimated $1.7K.
SouthState Corp first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 8 quarters.
SouthState Corp's Atea Pharmaceuticals position peaked at $70K in Q3 2021.
108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2023.

Based on SouthState Corp's 13F filing for Q4 2023, filed 6 Feb 2024.